Liraglutide
GLP-1 receptor agonist approved as Victoza for type 2 diabetes and Saxenda for weight management. Daily injectable with long-term safety data.
0 anonymous reports
Also known as:
victozasaxendalira
browse topics:
community guides:
No reports found.
Community Q&A
- How does liraglutide compare to semaglutide for weight loss?
- Community accounts consistently describe semaglutide as producing greater weight loss at equivalent effort, with liraglutide framed as the earlier generation. Accounts from users who transitioned from liraglutide to semaglutide or tirzepatide consistently describe stronger appetite suppression and faster results on the newer agents. Liraglutide appears in accounts primarily from those with prescriptions predating semaglutide's availability, or from those managing cost and access. Daily injection versus weekly for semaglutide is also cited as a practical disadvantage.
- What are the side effects of liraglutide?
- Community accounts describe a GI side effect profile similar to other GLP-1 agents — nausea, reduced appetite, and occasional vomiting, most pronounced in the first 4–8 weeks. Accounts that switched from semaglutide to liraglutide describe similar but slightly milder GI effects. Injection site reactions appear occasionally. The daily injection requirement produces more injection site rotation accounts than weekly agents. Pancreatitis concerns circulate in community discussions, though adverse events of this severity are rarely described in confessions.